NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow BioSciences, the biotechnology subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), continues its negotiations toward a definitive agreement with emerging biotech innovator Amarantus BioSciences (OTCBB: AMBS). RBCC is in talks to provide funding and expertise toward the development and marketing of one or more of Amarantus’ exciting medical breakthroughs. The company is developing thrilling new ways to effectively diagnose and treat devastating neurological disorders including Parkinson’s disease and Traumatic Brain Injury (TBI).
